3 results
The primary objective is to evaluate health related QoL under an oral sequential treatment with natural steroid hormones: Duogestan®. The secondary objective is to evaluate the bleeding patterns over a one-year period.
The primary objective is to show a difference in responder rates between the study product (T4020) and the vehicle : a reduction of 50% or more in keratitis/ulcer area from baseline (inclusion visit = V2 = Day 0) assessed at Day 28 (Visit 6).
Primary Objective:To establish the maximum tolerated healthy liver-absorbed dose of 166Ho-microspheres in patients with HCC who receive RL as a bridge to resection.Secondary Objective(s): 1) To establish dose-response relationships between:a. The…